HDAC-IN-51 

HDAC-IN-51 is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.32, 0.353, 0.431, 0.515, and 85.4 μM for HDAC10, HDAC1, HDAC2, HDAC3 and HDAC11, respectively. HDAC-IN-51 induces cell cycle arrest and apoptosis, modulating cell cycle-/apoptosis-related miRNAs expression. HDAC-IN-51 can be used in research of cancer^[1].

HDAC-IN-51 (compound 8d; 1 nM-10 μM; 48 h) has antiproliferative activity with IC₅₀ values of 0.54, 0.56, and 1.35 μM for K562, HCT116, and A549 cells, respectively^[1].
HDAC-IN-51 (1 and 5 μM; 24 and 48 h; U937 leukaemia cells) arrests cell cycle at the G1 phase^[1].
HDAC-IN-51 (1 and 5 μM; 48 h; U937 cells) induces apoptosis and down-regulates miRNAs with antiapoptotic activity (miR-17-5p, miR-18-5p, miR-19b-3p, miR-20a-5p,miR-21-5p)^[1].
HDAC-IN-51 (1 and 5 μM; 48 h; U937 cells) increases mRNA expression of p21, BAX and BAK, down-regulates cyclin D1 and BCL-2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

436.51

C₂₇H₂₄N₄O₂

3026728-28-6

NC1=CC=CC=C1NC(C2=NC=C(C=C2)NC(C(C3=CC=CC=C3)CC4=CC=CC=C4)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Di Bello E, et, al. Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells. Eur J Med Chem. 2022 Dec 15;247:115022.  [Content Brief]